SHPPF Stock Chart & Stats
$64.80
$0.00(0.00%)
At close: 4:00 PM EDT
$64.80
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$39.84 - $97.45
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$1.80B
Enterprise Value$1.58B
Total Cash (Recent Filing)$118.90M
Total Debt (Recent Filing)$354.70M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Oct 29, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding20,578,390
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.85
Price to Sales (P/S)0.45
P/FCF Ratio-23.25
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue0.49
Enterprise Value/Gross Profit2.43
Enterprise Value/Ebitda23.30
Forecast
1Y Price Target
$108.74Price Target Upside67.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$3.88B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid revenue expansion demonstrates increasing customer adoption and a growing market presence for Redcare Pharmacy. If maintained, this scale can improve purchasing leverage, support operating efficiencies, and provide a broader base for converting growth into sustainable profitability.
Improving Operating ProfitabilityThe improvement in EBITDA margin and materially narrower EBIT losses indicate that operating leverage is beginning to emerge as revenue scales. Continued margin progression could strengthen the business model by allowing growth to translate more effectively into earnings and internally generated funding.
Very Low Recent DebtThe latest balance sheet shows substantially reduced leverage and a meaningful equity base relative to debt. If the lower debt level is sustainable, Redcare Pharmacy has greater flexibility to absorb operational volatility, fund strategic investment, and avoid a heavy interest burden.
Bears Say
Persistent Net LossesDespite strong sales growth and improving EBITDA, Redcare Pharmacy has not yet produced consistent bottom-line profitability. Persistent net losses can erode equity over time, limit self-funded expansion, and show that the current operating model still needs further efficiency or margin improvement.
Weak Cash ConversionThe latest reversal to negative operating cash flow, combined with sharply negative free cash flow, weakens financial flexibility even as revenue expands. Continued cash outflows may require tighter working-capital management or external funding, making growth less valuable until cash conversion stabilizes.
Negative EPS GrowthNegative EPS growth indicates that per-share earnings performance is deteriorating rather than keeping pace with the company’s revenue expansion. This reinforces the concern that scale has not yet translated into durable shareholder earnings and places greater importance on successful margin improvement.
SHPPF FAQ
What was Redcare Pharmacy’s price range in the past 12 months?
Redcare Pharmacy lowest stock price was $39.84 and its highest was $97.45 in the past 12 months.
What is Redcare Pharmacy’s market cap?
Redcare Pharmacy’s market cap is $1.80B.
When is Redcare Pharmacy’s upcoming earnings report date?
Redcare Pharmacy’s upcoming earnings report date is Oct 29, 2026 which is in 4 days.
How were Redcare Pharmacy’s earnings last quarter?
Redcare Pharmacy released its earnings results on Jul 29, 2026. The company reported $0.257 earnings per share for the quarter, beating the consensus estimate of -$0.302 by $0.559.
Is Redcare Pharmacy overvalued?
According to Wall Street analysts Redcare Pharmacy’s price is currently Undervalued.
Does Redcare Pharmacy pay dividends?
Redcare Pharmacy does not currently pay dividends.
What is Redcare Pharmacy’s EPS estimate?
Redcare Pharmacy’s EPS estimate is 0.07.
How many shares outstanding does Redcare Pharmacy have?
Redcare Pharmacy has 20,578,390 shares outstanding.
What happened to Redcare Pharmacy’s price movement after its last earnings report?
Redcare Pharmacy reported an EPS of $0.257 in its last earnings report, beating expectations of -$0.302. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Redcare Pharmacy?
Currently, no hedge funds are holding shares in SHPPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Redcare Pharmacy Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$108.74 (67.81% Upside)
$108.74 (67.81% Upside)
Insider Transactions
Sold Shares
Worth $283.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.16%
12-Months-Change
Fundamentals
Return on Equity
-9.00%
Trailing 12-Months
Asset Growth
-7.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Redcare Pharmacy
Redcare Pharmacy N.V. manages and runs a network of digital pharmacies across Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. The company offers a comprehensive selection of healthcare products, including prescription medications, over-the-counter drugs, pharmacy-related beauty and personal care items, and nutritional supplements. Established in 2001, the firm, initially known as Shop Apotheke Europe N.V., officially rebranded to Redcare Pharmacy N.V. in June 2023. Its operational headquarters are situated in Sevenum, the Netherlands.
SHPPF Stock 12 Month Forecast
Average Price Target
$108.74
▲(67.81% Upside)
Technical Analysis
Ownership Overview
2.11% Insiders
8.23% Mutual Funds
<0.01% Other Institutional Investors
84.10% Public Companies and
Individual Investors